Can-Fite BioPharma Ltd. (CANF) Key Metrics
CANF valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $5.3M
- Enterprise value
- −$2.2M
- P/E (TTM)
- —
- Forward P/E
- 3.0
- PEG ratio
- —
- Price / sales
- 13.2
- Price / book
- 1.0
- EV / EBITDA
- 0.1
- Dividend yield
- —
- Beta
- −0.02
CANF key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCANF returns How much profit the business earns on the capital it uses.
Return on equity−44.7 pts
−179.7%
2025 · hover or tap a bar for each year
20162025
Return on assets−23.8 pts
−106.3%
2025 · hover or tap a bar for each year
20162025
Asset turnover−37.9%
0.04
2025 · hover or tap a bar for each year
20162025
CANF financial health Debt, liquidity and how easily interest is covered.
Debt / equity−33.6%
0.01
2025 · hover or tap a bar for each year
20162025
Net debt−$685,869
−$8.5M
2025 · hover or tap a bar for each year
20162025
Current ratio−21.0%
3.46
2025 · hover or tap a bar for each year
20162025
Interest coverage
-710.7
2025 · hover or tap a bar for each year
20162025
Debt / assets−34.6%
0.01
2025 · hover or tap a bar for each year
20162025
CANF efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+26 days
68 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding−13,695 days
13,421 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle+13,721 days
-13,354 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue−0.2 pts
0.5%
2025 · hover or tap a bar for each year
20162025
CANF returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CANF debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CANF cash returned to shareholders
DividendsBuybacksFree cash flow
CANF price vs earnings per share
Share price at year-endEPS (right axis)
CANF key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | — | — | — | — | — | — | — | — | — | $98.86B |
| Enterprise value | — | — | — | — | — | — | — | — | — | $98.86B |
| Earnings yield | — | — | — | — | — | — | — | — | — | −0.0% |
| Free cash flow yield | — | — | — | — | — | — | — | — | — | −0.0% |
| Shareholder yield (dividends + buybacks) | — | — | — | — | — | — | — | — | — | 0.0% |
| Share price at fiscal year-end | $4.00 | $32.50 | $44.00 | $122.60 | $258.00 | $356.00 | $660.00 | $3,780.00 | $4,440.30 | $7,140.00 |
| Per share | ||||||||||
| Revenue per share | — | — | — | — | — | — | — | — | — | $0.01 |
| Earnings per share | — | — | — | — | — | — | — | — | — | −$0.50 |
| Operating cash flow per share | — | — | — | — | — | — | — | — | — | −$0.64 |
| Free cash flow per share | — | — | — | — | — | — | — | — | — | −$0.65 |
| Cash per share | — | — | — | — | — | — | — | — | — | $0.59 |
| Book value per share | — | — | — | — | — | — | — | — | — | $0.28 |
| Tangible book value per share | — | — | — | — | — | — | — | — | — | $0.28 |
| Capex per share | — | — | — | — | — | — | — | — | — | $0.00 |
| Debt per share | — | — | — | — | — | — | — | — | — | $0.04 |
| Shares outstanding | — | — | — | — | — | — | — | — | — | 13.8M |
| Change in shares outstanding | — | — | — | — | — | — | — | — | — | +20.6% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −179.7% | −134.9% | −142.5% | −108.6% | −123.1% | −339.2% | −462.7% | −216.5% | −143.6% | −97.3% |
| Return on assets (ROA) | −106.3% | −82.5% | −79.2% | −69.3% | −84.6% | −163.2% | −156.6% | −83.3% | −55.2% | −49.7% |
| Return on tangible assets | −104.1% | −86.4% | −76.4% | −110.3% | −62.2% | −151.7% | −154.5% | −82.6% | −63.4% | −67.8% |
| Free cash flow margin | — | — | — | — | — | — | −533.3% | −109.6% | — | — |
| Financial health | ||||||||||
| Total debt | $70,998 | $104,000 | $40,000 | $62,000 | $124,000 | $67,000 | $75,000 | — | $998,101 | $564,752 |
| Cash & short-term investments | $8.5M | $7.9M | $8.9M | $8.0M | $19.1M | $8.3M | $2.8M | $3.9M | $3.5M | $8.1M |
| Net debt | −$8.5M | −$7.8M | −$8.9M | −$7.9M | −$19.0M | −$8.3M | −$2.7M | −$3.9M | −$2.5M | −$7.5M |
| Debt / equity | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | — | 0.33 | 0.15 |
| Debt / assets | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | — | 0.13 | 0.06 |
| Current ratio | 3.46 | 4.38 | 4.90 | 3.66 | 7.35 | 7.41 | 2.18 | 2.53 | 3.82 | 4.04 |
| Quick ratio | 3.46 | 4.38 | 4.90 | 3.68 | 7.37 | 7.48 | 2.40 | 3.81 | 5.66 | 4.04 |
| Interest coverage | -710.7 | -580.7 | -585.4 | -160.3 | -56.6 | -39.0 | -28.1 | -4.5 | -6.7 | -316.3 |
| Working capital | $6.7M | $6.9M | $7.9M | $6.7M | $17.3M | $8.1M | $3.9M | $4.8M | $5.1M | $7.6M |
| Invested capital | −$2.9M | −$2.3M | −$2.6M | −$3.4M | −$4.6M | −$2.2M | −$244,000 | −$873,000 | $555,012 | −$3.7M |
| Tangible asset value | $5.6M | $5.4M | $6.2M | $4.5M | $14.4M | $6.1M | $2.4M | $3.0M | $3.1M | $3.9M |
| Net current asset value | $5.5M | $5.3M | $6.2M | $4.3M | $14.2M | $6.0M | $1.4M | $3.0M | $2.1M | $3.8M |
| Graham net-net per share | — | — | — | — | — | — | — | — | — | $0.13 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | $2.6M | $715,000 | — | — | — | — | — |
| Share buybacks (net) | — | — | — | — | — | — | $0 | $0 | $0 | $0 |
| Capex / revenue | 0.5% | 0.7% | 0.3% | 1.1% | 1.3% | 3.4% | 0.1% | 0.9% | 0.8% | 6.1% |
| Capex / depreciation | 0.08 | 0.71 | 0.13 | 0.64 | 0.79 | 2.17 | 0.21 | 2.36 | 0.35 | 0.56 |
| Stock-based compensation / revenue | 83.3% | 53.7% | 35.1% | 32.5% | 46.7% | 46.5% | 18.9% | 14.0% | 23.1% | 182.3% |
| R&D / revenue | 1,652.6% | 854.2% | 805.2% | 958.4% | 1,154.7% | 1,566.3% | 540.2% | 159.0% | 624.0% | 3,585.9% |
| SG&A / revenue | 897.1% | 452.1% | 399.7% | 388.0% | 450.8% | 386.8% | 150.7% | 82.7% | 349.1% | 1,590.8% |
| Efficiency | ||||||||||
| Days sales outstanding | 67.5 | 42.0 | 30.7 | 21.4 | 14.1 | 156.7 | 417.8 | 352.8 | 732.7 | 90.3 |
| Days of inventory on hand | — | — | — | — | — | — | -16,779.3 | -15,267.4 | 535,114.4 | — |
| Days payables outstanding | 13,421.4 | 27,116.8 | 16,097.6 | — | — | — | 11,547.6 | 5,233.0 | -216,409.6 | -624,855.6 |
| Cash conversion cycle (days) | -13,353.9 | -27,074.8 | -16,066.9 | — | — | — | -27,909.1 | -20,147.7 | 752,256.7 | 624,945.8 |
| Receivables turnover | 5.41 | 8.70 | 11.89 | 17.05 | 25.85 | 2.33 | 0.87 | 1.03 | 0.50 | 4.04 |
| Payables turnover | 0.03 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 | 0.03 | 0.07 | −0.00 | −0.00 |
| Asset turnover | 0.04 | 0.07 | 0.08 | 0.05 | 0.06 | 0.09 | 0.25 | 0.48 | 0.09 | 0.01 |
| Average receivables | $75,498 | $77,500 | $62,500 | $47,500 | $33,000 | $327,500 | $2.3M | $3.7M | $1.7M | $41,915 |
| Average payables | $889,490 | $522,500 | $661,500 | $925,000 | $757,500 | $1.4M | $1.6M | $1.2M | $1.3M | $855,384 |
| Average inventory | — | — | — | −$43,500 | −$70,500 | −$404,000 | −$2.3M | −$3.6M | −$3.3M | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from CANF's annual financial statements (latest annual report filed March 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CANF valuation and financial ratios
Can-Fite BioPharma earned a return on equity of −179.7% in fiscal 2025. It ended the year with $0.1 million of debt and $8.5 million in cash and short-term investments, a net cash position of $8.5 million.
See the CANF income statement, the CANF chart for price history, or the CANF stock overview for the latest quote and news.
CANF key metrics FAQ
What is Can-Fite BioPharma's return on equity?
Can-Fite BioPharma's return on equity (ROE) was −179.7% in fiscal 2025: net income of -$9.9 million on average shareholders' equity of $5.5 million.
How much debt does Can-Fite BioPharma have?
Can-Fite BioPharma had total debt of $0.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
What is Can-Fite BioPharma's current ratio?
Can-Fite BioPharma's current ratio was 3.46 at the end of fiscal 2025: current assets were 3.46 times current liabilities.